A US medical panel has recommended resuming the use of the Johnson & Johnson COVID-19 vaccine.
The recommendation came from advisers to the US Centers for Disease Control and Prevention (CDC).
The vaccine was paused by the CDC and US Food and Drug Administration last week after reports of rare but serious blood clots associated with low blood platelets.
Johnson & Johnson’s vaccine, which is given as a single jab as opposed to the traditional two doses, has been administered to almost eight million people in the US.
The American government is now likely to quickly resume use of the jab.
It has not yet been approved for use in the UK, but 30 million doses have bene ordered.
“The benefits do clearly outweigh the risk from a population and individual perspective,” said Dr Beth Bell, a member of the CDC advisory panel.
“It’s a new risk. It’s admittedly an extremely small risk and smaller than many other risks that we choose to take every